Jasinska-Myga Barbara, Opala Grzegorz, Goetz Christopher G, Tustanowski Jerzy, Ochudlo Stanislaw, Gorzkowska Agnieszka, Tyrpa Jadwiga
Department of Neurology, Ageing, Degenerative and Cerebrovascular Diseases, Medical University of Silesia, Central University Hospital, Medykow 14, Katowice 40-752, Poland.
Arch Neurol. 2007 Feb;64(2):261-5. doi: 10.1001/archneur.64.2.261.
Apolipoprotein E gene (APOE) polymorphism is an important determinant for the development of various cardiovascular and neurodegenerative disorders. There have been conflicting reports of association of APOE polymorphism with dementia in Parkinson disease (PD).
To determine the relationship between APOE polymorphisms and plasma cholesterol concentration, and PD with dementia (PDD).
Four-year (1999-2002) case-control study.
Academic medical center with inpatient and outpatient movement disorders services. Patients Consecutive white patients of the same ethnic background with PD.
Strict clinical, neuropsychological, and neuroimaging criteria were used to exclude dementia with Lewy bodies, Alzheimer disease, and vascular dementia. Findings were compared in 2 clinical groups, including 98 patients (47 men and 51 women; mean age, 71 years) with PDD and 100 patients (52 men and 48 women; mean age, 62 years) with PD without dementia.
Analysis of APOE genotypes and allelic frequency (polymerase chain reaction) and plasma cholesterol concentration (enzymatic assay) were evaluated by a clinician blinded to the clinical diagnosis, and findings were compared between the groups with PDD or PD without dementia. Multiple stepwise regression analysis and the Spearman rank correlation coefficient were used to evaluate relationships between dementia and both APOE polymorphism and cholesterol concentration. Statistical significance was set at P<.05.
Epsilon4 allele frequencies were similar in PDD and PD without dementia (16.8% vs 19%, respectively). Cholesterol concentration, APOE genotypes, and allelic frequencies did not relate to PDD.
In contrast to Alzheimer disease, when PDD is carefully defined, it is clearly not associated with APOE polymorphisms or with a distinctive plasma cholesterol profile. Ongoing longitudinal follow-up with emphasis on autopsy recruitment will enable further analyses of biochemical alterations underlying PDD.
载脂蛋白E基因(APOE)多态性是多种心血管疾病和神经退行性疾病发生发展的重要决定因素。关于APOE多态性与帕金森病(PD)痴呆症之间的关联,已有相互矛盾的报道。
确定APOE多态性与血浆胆固醇浓度以及PD伴痴呆症(PDD)之间的关系。
为期四年(1999 - 2002年)的病例对照研究。
设有住院和门诊运动障碍服务的学术医疗中心。研究对象为具有相同种族背景、连续入选的白人PD患者。
采用严格的临床、神经心理学和神经影像学标准,排除路易体痴呆、阿尔茨海默病和血管性痴呆。在两个临床组中比较研究结果,包括98例PDD患者(47例男性和51例女性;平均年龄71岁)和100例无痴呆的PD患者(52例男性和48例女性;平均年龄62岁)。
由对临床诊断不知情的临床医生评估APOE基因型和等位基因频率(聚合酶链反应)以及血浆胆固醇浓度(酶法测定),并比较PDD组或无痴呆的PD组之间的研究结果。采用多元逐步回归分析和Spearman等级相关系数评估痴呆与APOE多态性及胆固醇浓度之间的关系。设定P<0.05为具有统计学意义。
PDD组和无痴呆的PD组的ε4等位基因频率相似(分别为16.8%和19%)。胆固醇浓度、APOE基因型和等位基因频率与PDD无关。
与阿尔茨海默病不同,当对PDD进行仔细界定时,它显然与APOE多态性或独特的血浆胆固醇谱无关。持续的纵向随访,重点是尸检招募,将有助于进一步分析PDD潜在的生化改变。